Global drugmakers accelerating US presence amid looming tariff threatsExecutive summary: Global drugmakers are accelerating investments and expansions in the United States as they respond to the prospect of new tariffs on imported pharmaceuticals. Such moves could reshape the US pharmaceutical supply chain, increase domestic production capacity, and affect pricing dynamics in the sector. Major pharmaceutical companies such as Pfizer, Merck and Johnson & Johnson, together with US policymakers and regulators, are central to this shift. Analysts expect continued capital allocation toward US facilities, potential mergers, and intensified lobbying for favorable trade policies.Global pharmaceutical companies are speeding up expansion plans in the United States as policymakers signal potential tariffs on imported drugs. The development reflects shifting supply‑chain strategies and heightened political pressure on the sector. No concrete tariff measures have been enacted yet, but the prospect is driving capital reallocation.Open the full case file on Beyond →
Social Pulse
AI estimate · not scraped